Compare JPMorgan Chase & Co (JPM) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Summit Therapeutics Inc — how do they compare? JPMorgan Chase & Co trades at $344.86 (market cap $900.78B), while Summit Therapeutics Inc trades at $14.47 (market cap $10.48B). The key difference: JPMorgan Chase & Co is far larger — about 86× Summit Therapeutics Inc's market cap, and JPMorgan Chase & Co pays a 1.77% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| JPM | SMMT | |
|---|---|---|
Market Cap | $900.78B | $10.48B |
Volume | 10,479,943 | — |
Sector | Financials | Health |
52-Week High | $346.91 | $29.32 |
52-Week Low | $282.84 | $13.05 |
Dividend Yield | 1.77% | — |
Enterprise Value | — | $9.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $345.10, up 1.17% on the day, with strong technical momentum as the stock approaches resistance at $347. The company reported mixed Q4 2025 earnings but beat expectations in Q1 and Q2 2026, with revenue growing to $181.85 billion in 2025. Analyst sentiment remains positive with a consensus price target of $372.73, representing 8% upside potential from current levels.
JPMorgan demonstrates solid fundamentals with a reasonable P/E of 14.52 and strong net income margin of 33.4%. However, negative operating cash flow of -$147.78 billion in 2025 and geopolitical risks highlighted by CEO Jamie Dimon present headwinds. The stock offers value for long-term investors but faces near-term volatility from earnings uncertainty and macroeconomic concerns.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.
The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
